

1 **VIDAS® TB-IGRA accuracy in tuberculosis patients and persons at varying risk of**
2 **exposure**

3 **Supplementary Information**

4 *Study sites*

5 **Site FR01**

6 Etablissement Français du Sang (EFS), Lyon, Auvergne Rhône-Alpes, France
7 Yves Mérieux, Francis Camoin, Marie-Christine Lambert, Carine Marliere
8 Clinical Affairs laboratory, bioMérieux, Marcy l'étoile, France
9 Laurence Bridon, Pauline Fabre, Aurélie Langlet, Florence Senot, Isabelle Millon

10

11 **Site FR02**

12 Lariboisière Hospital, Paris, France
13 Dr. Amanda Lopes, Prof Emmanuelle Cambau, Dr Faiza Mougari, Prof Philippe Manivet, Claire Pernin,
14 Lydia Suarez, Valerie Andrianasolonirina, Véronique Delasse

15

16 **Site FR03**

17 Avicenne Hospital, Paris, France
18 Dr. Frédéric Méchaï, Fadhila Messani, Miassa Slimani, Ingrid Jacquelin. Laboratory (TB culture): Pr.
19 Etienne Carbonnelle, Laure Poulet

20

21 **Site FR04**

22 CHU de Saint-Etienne 42055 Saint-Etienne cedex 02
23 Prof. Elisabeth Botelho-Nevers.
24 Infectious diseases: Dr Amandine Gagneux-Brunon, Dr Anne Fresard, Veronique Ronat, Philippine
25 Bourrassaud, Anne Pouvaret. Pneumology: Prof Jean Michel Vergnon, Dr Marios Froudarakis, Rémi
26 Chapelon. Dermatology: Prof Jean Luc Perrot, Marie Chazelle. Rheumatology: Prof Hubert Marotte,
27 Hervé Locrelle. Occupational Medicine: Prof Luc Fontana, Marie Christine Coquet. Laboratory: Dr
28 Claude Lambert, Dr Anne Berger, Alice Haccourt, Alice Chanavat

29

30 **Site FR05**

31 Anti-TB center of Chambéry, Chambéry, France
32 Dr. Margaux Isnard, Dr Cécile Descotes-Genon, Ms Marie-Christine Carret, Mr Tarik Habet, Dr Marion
33 Levast, Ms Evelyne Capitan, Corinne Bernati

34

35 **Site FR06**

36 Lapeyronie Hospital, Montpellier, France
37 Dr. Edouard Tuailon.
38 Infectious diseases: Quam Edem Aquereburu. Rheumatology: Prof Jacques Morel, Beatrice Tinland,
39 Sylvie Gouilloux. Occupational Medicine: Dr François-Xavier Lesage, Dr Guillaume Choron, Xavier
40 Loche. Laboratory: Dr Amandine Pisoni, Brigitte Burrut, Françoise Bel.

41

42 **Site FR07**

43 Anti-TB center of Nanterre, Nanterre, France
44 Dr. Amel Medjahed-Artebasse

45

- 46 **Bacteriology laboratory, Antoine Bèclère Hospital (APHP), Clamart, France**
47 *Testing of samples from sites FR03 and FR07*
48 Pr Doucet- Populaire Florence, Dr Christelle Guillet-Caruba, Rachida Aït El Far, Sandrine Roze, Daniel
49 Martinho
50
51 **Site GB01**
52 St Thomas' Hospital, London, UK
53 Dr. Ronan Breen, Arbane Gill, Laletha Agoramoorthy
54
55 **Site GB02**
56 Evelina London Children's Hospital, London, UK
57 Dr. Julia Kenny, Dr Marc Tebruegge, Bethany Hamilton, Christian Henderson, Daniella Hydes
58
59 **CIDR Laboratory (Centre for Clinical Infection & Diagnostics Research)**
60 *VIDAS testing for sites GB01 and GB02*
61 Dr. Rahul Batra, Amita Patel, Bindi Patel
62
63 **Site IT01**
64 INMI L. Spallanzani, Rome, Italy
65 Dr. Delia Goletti, Dr Elisa Petruccioli, Dr Gina Gualano, Valentina Vanini, Gilda Cuzzi
66
67 **Site ME01**
68 Autonomous University of Baja California, Mexicali, Mexico
69 Dr. Julia Dolores Estrada Guzman, Dr Rosa Herrera-Torres, Dr Zuceth Duran-Gomez, Dr Fernanda
70 Cervantes-Lopez, Dr Rene Machado-Contreras, Salvador Josaet Cervantes-Borrego, Yosef Dueñez-
71 Uriarte
72
73 **Site US01**
74 Rutgers University, Newark, NJ (USA)
75 Dr. Maria Laura Gennaro, Dr Alfred Lardizabal, Deborah Handler, Dr. Natalie Bruiners, Dr. Rahul Ukey,
76 Blas Peixoto, Alberta Onyuka, Ariana Alcaide
77
78 **Collaborating hospitals with US01**
79 Doreen Dutchak RN, and Christian Engell, MD, Newark Beth Israel Medical Center
80 Mabel La Forgia, RN, and Joseph DePasquale, MD, Jersey City Medical Center
81
82 **Site US02**
83 University of California San Diego, San Diego, CA (USA)
84 Dr. David T. Pride, Nathan Kendrick, Steven Hendrickx, Stephanie Solso, Helene Le, Joseph Lencioni,
85 Rueben Barba, Maria Pizzaro, Jenny Shin
86
87 **Site US04**
88 Stanford University, Palo Alto, CA (USA)
89 Dr. Niaz Banaei, Arena Shafeque, Fiona Senchyna
90
91 **Site US05**
92 Saint Louis University, St Louis, MO (USA)
93 Dr. Daniel Hoft, Dr. Azra Blazevic, Linda Eggemeyer-Sharpe, Janice Tennant, Sabrina Dipiazza, Kate
94 Lierfer, Joan Siegner, Amanda Nethington, Tammy Blevins, Yinyi Yu, Huan Ning
95

96 **Site US06**

97 National Jewish Health, Denver, CO (USA)

98 Dr. Charles Daley, Dr Robert Belknap, Dr Michael Wilson, Michael Higgins, Kaylynn Aiona

99

100 **Site US07**

101 University of Illinois, Chicago, IL (USA)

102 Dr Nahed Ismail, Dr Susan Bleasdale, Anh Nguyen, Iuliana Bentea, Brenna Lindsey

103

104 **Site ZA01**

105 University of Cape Town, Cape Town, South Africa

106 Prof. Keertan Dheda, Dr Aliasgar Esmail, Dr Suzette Oelofse, Dr Lynelle Mottay, Marietjie Pretorius,

107 Richard Meldau, Carley Mandviwala, Maria Gorgel, Eleanor Pretorius, Solomri Foloti, Lusanda Yenani,

108 Vonnita Loren, Wasiela Galant

109

110 **Site ZA02**

111 TASK Applied Science, Cape Town, South Africa

112 Dr Naadira Vanker, Dr Caryn Upton, Michelle Eriksson, Martha Jacobs, Anastacia Arendse, Wendy

113 Wakens, Dorothy Zakariya, Alexandra Waltman, Chantell Meyer, Margaret Muller, Michele van Rooyen,

114 Phumza Setlaba, Patricia Maunder, Mlungisi Mnuu, Doreen Petersen, Charné Rossouw, Magdalene

115 Kennedy, Silvia Nunes, Thirumani Govender, Lize Greyling, Jacqueline Russouw, Katriena Ross, Tracy

116 Jack, Kurt McQuire, Diane Lavies, Beulah Classen, Carmen Kleinhans, Julia Sims, Bryan Esterhuizen,

117 Sven Friedrich, Cebisa Mdladla, Bongiwwe Gwadela, Fay Swanson, Pascal Musoni, Dustin Bosch, Lucille

118 October, Atica Moosa, Karabo Mahlangu, Olwethu Ngxisho, Chaldene Johannes, Chantal Botha, Alta

119 Mwela, Leylani Croy

120

121

122 *Supplementary Methods*

123 Sensitivity of QFT-Plus and VIDAS® TB-IGRA were independently calculated, as follows:

124
$$\text{Sensitivity} = 100 * \frac{TP}{TP + FN}$$

125 where TP = true positives (*i.e.*, culture-confirmed TB disease and positive test result) and

126 FN = false negatives (*i.e.*, culture-confirmed TB disease and negative test result).

127

128 To evaluate the VIDAS® TB-IGRA accuracy for the mixed exposure risk population, positive

129 percent agreement (PPA) and negative percent agreement (NPA) relative to the QFT-Plus were

130 calculated as follows, along with the 95% confidence interval (95%CI).

131
$$\text{PPA} = 100 * \frac{a}{a + c} \quad \text{and} \quad \text{NPA} = 100 * \frac{d}{d + b}$$

132 where a, b, c, and d are defined as follows:

		QFT-Plus result		Total
		Positive	Negative	
VIDAS® TB-IGRA result	Positive	a	b	a+b
	Negative	c	d	c+d
Total		a+c	b+d	a+b+c+d

133

134

135 *Supplementary Tables and Figures*136 **Supplementary Table S1.** Study sites for the TB disease and mixed exposure risk populations.

Region	Country	Site Code	Site name / City	Principal Investigator	Site responsibilities	TB disease Patients (n = 200)	Mixed exposure risk Participants (n = 1460)
EU	France	FR01*	Clinical Affairs Laboratory, bioMérieux / Marcy l'Etoile	Laurence Bridon	VIDAS testing	–	125
EU	France	FR02	Lariboisière Hospital / Paris	Dr. Amanda Lopes	Recruitment, Testing (QFT-Plus and VIDAS)	5	–
EU	France	FR03**	Avicenne Hospital / Paris	Dr. Frederic Méchaï	Recruitment	3	2
EU	France	FR04	North Hospital / St. Etienne	Prof. Elisabeth Botelho-Nevers	Recruitment, Testing (QFT-Plus and VIDAS)	4	91
EU	France	FR05	Anti-TB center of Chambéry	Dr. Margaux Isnard	Recruitment, Testing (QFT-Plus and VIDAS)	5	45
EU	France	FR06	Lapeyronie Hospital / Montpellier	Dr. Edouard Tuaillon	Recruitment, Testing (QFT-Plus and VIDAS)	–	86
EU	France	FR07**	Anti-TB center of Nanterre	Dr. Amel Medjahed	Recruitment	–	127
EU	UK	GB01***	St Thomas' Hospital / London	Dr. Ronan Breen	Recruitment	1	11
EU	UK	GB02****	Evelina London Children's Hospital	Dr. Marc Tebruegge replaced by Dr Julia Kenny	Recruitment	–	3
EU	Italy	IT01	INMI L. Spallanzani-IRCCS / Rome	Dr. Delia Goletti	Recruitment, Testing (QFT-Plus and VIDAS)	5	28
US	USA	US01	Rutgers University / Newark	Dr. Maria Laura Gennaro	Recruitment, Testing (QFT-Plus and VIDAS)	17	77
US	USA	US02	University of California / San Diego	Dr. David T. Pride	Recruitment, Testing (QFT-Plus and VIDAS)	–	5
US	USA	US04	Stanford University / Palo Alto	Dr. Niaz Banaei	Recruitment, Testing (QFT-Plus and VIDAS)	–	144
US	USA	US05	Saint Louis University	Dr. Daniel Hoft	Recruitment, Testing (QFT-Plus and VIDAS)	–	207
US	USA	US06	National Jewish Health / Denver	Dr. Charles Daley	Recruitment, Testing (QFT-Plus and VIDAS)	–	100

US	USA	US07	University of Illinois / Chicago	Dr Nahed Ismail	Recruitment, Testing (QFT-Plus and VIDAS)	–	179
ROW	Mexico	ME01	Autonomous University of Baja California / Mexicali	Dr. Julia Dolores Estrada Guzman	Recruitment, Testing (QFT-Plus and VIDAS)	3	77
ROW	South Africa	ZA01	University of Cape Town	Prof. Keertan Dheda	Recruitment, Testing (QFT-Plus and VIDAS)	105	74
ROW	South Africa	ZA02	TASK Applied Science / Cape Town	Dr. Naadira Vanker	Recruitment, Testing (QFT-Plus and VIDAS)	52	79

137

* For the additional responsibilities:

138

- Recruitment was performed by the national French organization for blood donation (EFS) Auvergne Rhône-Alpes

139

- QFT®-Plus testing was performed by St Etienne Hospital (site FR04 laboratory)

140

** Testing (QFT-Plus and VIDAS) was performed by Antoine Béclère Hospital (APHP), Bacteriology laboratory, Clamart, France

141

*** For the additional responsibilities:

142

- QFT-Plus testing was performed by TDL Trials - The Doctors Laboratory

143

- VIDAS testing was performed by CIDR (Centre for Clinical Infection & Diagnostics Research) Guy's and St Thomas' NHS Foundation Trust, London

144

Abbreviations: EU, European Union; ROW, Rest of the World; US, United States.

145

146 **Supplementary Table S2.** Criteria for stratification of the mixed exposure risk population based
 147 on TB-exposure risk level.

TB-exposure risk		Criteria	Number of individuals (%)	
Aggregate Low	Extremely Low	Blood donors from low burden countries, without known TB-exposure risk factors	125 (8.6%)	333 (22.8%)
	Very Low	Persons without known TB-exposure risk who were screened for TB infection prior to or during immunosuppressive therapy	90 (6.2%)	
	Low	Medical students in low TB-burden countries without known TB-exposure risk factors	118 (8.1%)	
Aggregate Medium	Medium Low	Healthcare workers or volunteers without known TB-exposure risk factors	598 (41.0%)	679 (46.5%)
	Medium	Persons from TB-related settings in low TB-burden countries	13 (0.9%)	
	Medium High	Immigrants or residents of countries with high TB incidence Persons who spent >1 month in an area with high TB incidence	68 (4.7%)	
Aggregate High	High	TB-case contacts (non-household)	296 (20.3%)	447 (30.6%)
	Very High	TB-case contacts (same house)	81 (5.6%)	
	Extremely High	TB-case contacts (same bedroom)	70 (4.8%)	

148
 149

150 **Supplementary Table S3.** Institutional Review board (IRB) or Independent Ethics Committee
 151 (IEC) approval codes for each study operating site. All sites complied with the Declaration of
 152 Helsinki, the International Council for Harmonisation of Technical Requirements for
 153 Pharmaceuticals for Human Use (ICH) Good Clinical Practice (GCP) guidelines as applicable to
 154 *in vitro* diagnostic (IVD) studies, and the laws and regulations of their respective countries. The
 155 Principal Investigator of each site was responsible for ensuring compliance with these regulations
 156 and adherence to approved protocols, and written informed consent was obtained from all study
 157 participants.

Site Code	Country	IRB/IEC Code
FR01	France	N/A (French Blood Bank)
FR02 FR03 FR04 FR05 FR06 FR07	France	2019-A00998-49
GB01 GB02	UK	CTPR01 IRAS: 265866; REC: 19/WA/0284 CTPR02 IRAS: 266217; REC: 19/WA/0285 REC: Wales REC 7
IT01	Italy	INMI "L. Spallanzani" Ethics Committee approval n°35/2019
ME01	Mexico	02-01-HGMXL/FMED-UABC-2019-08-29-254
US01	USA	CTPR01: Pro2019001840; CTPR02: Pro2019001936
US02 US05 US06	USA	WIRB Tracking Number CTPR01: 20191965; CTPR02: 20192037; CTPR03: 20192039
US04	USA	eProtocol#: 53485
US07	USA	2019-1145
ZA02	South Africa	Pharma ethics CTPR01: 190822774; CTPR02: 190822777 SAHPRA CTPR01: MD20190803; CTPR02: MD20190804 University of Cape Town Human Research Ethics Committee CTPR01 and 2: 840/2019

158 **Abbreviations:** IRAS, Integrated Research Application System; SAHPRA, South African Health
 159 Products Regulatory Authority; REC, Research Ethics Committee; WIRB, Western Institutional Review
 160 Board.

161 **Supplementary Table S4.** Cut-off values and result interpretation for the VIDAS® TB-IGRA
 162 assay.

NIL (IU/ml)	AG-NIL (IU/ml)	MIT-NIL (IU/ml)	Interpretation	Clinical Significance
< 6.40	≥ 0.35 and ≥25% NIL	Any	Positive	<i>M. tb</i> infection likely
	< 0.35 or ≥ 0.35 and < 25% NIL	≥ 1.1	Negative	<i>M. tb</i> infection not likely
		< 1.1	INDETERMINATE MIT Low	Likelihood of <i>M. tb</i> infection cannot be determined
≥ 6.40	Any		INDETERMINATE NIL High	Likelihood of <i>M. tb</i> infection cannot be determined

163 **Abbreviations:** AG, antigen; MIT, mitogen (positive control); NIL, negative control.

164


165 **Supplementary Table S5.** Negative percent agreement (NPA) and positive percent agreement
 166 (PPA) for the VIDAS® TB-IGRA relative to the QFT-Plus test for individuals in the mixed
 167 exposure risk population at nine levels of risk for TB, ranging from extremely low to extremely
 168 high. NPA and PPA were also calculated for the three main levels of TB exposure: aggregate low,
 169 medium, and high.

TB-Exposure Risk	QFT-Plus Negative results (n=1217)				QFT-Plus Positive results (n=242)			
	n	VIDAS® TB-IGRA		NPA [95% CI]	n	VIDAS® TB-IGRA		PPA [95% CI]
		Neg.	Pos.			Pos.	Neg.	
Extremely Low	119	119	0	100% [96.9, 100.0]%	6	3	3	50.0% [18.8, 81.2]%
Very Low	84	78	6	92.9% [85.3, 96.7]%	6	4	2	66.7% [30.0, 90.3]%
Low	117	113	4	96.6% [91.5, 99.1]%	1	1	0	100.0% [2.5, 100.0]%
Aggregate Low	320	310	10	96.9% [94.3, 98.5]%	13	8	5	61.5% [35.5, 82.3]%
Medium Low	593	550	43	92.7% [90.4, 94.6]%	5	2	3	40.0% [11.8, 76.9]%
Medium	13	12	1	92.3% [66.7, 98.6]%	0	N/A	N/A	N/A
Medium High	31	25	6	80.6% [63.7, 90.8]%	37	34	3	91.9% [78.7, 97.2]%
Aggregate Medium	637	587	50	92.2% [89.8, 94.0]%	42	36	6	85.7% [72.2, 93.3]%
High	184	144	40	78.3% [71.8, 83.6]%	112	104	8	92.9% [86.5, 96.3]%
Very High	45	36	9	80.0% [66.2, 89.1]%	36	36	0	100.0% [90.3, 100.0]%
Extremely High	31	20	11	64.5% [46.9, 78.9]%	39	39	0	100.0% [91.0, 100.0]%
Aggregate High	260	200	60	76.9% [71.4, 81.6]%	187	179	8	95.7% [91.7, 98.1]%

170 **Abbreviations:** CI, confidence interval; QFT-Plus, QuantiFERON Plus.

171


172



* patients not included in sensitivity computations:
 • 76 patients with negative TB-culture
 • 55 patients with positive TB-culture due to sequential design

173
174
175
176

Supplementary Figure S1. Flow of participants through the study.



177

178


179

180

Supplementary Figure S2. Distribution of interferon (IFN)- γ concentrations measured by the QFT-Plus and VIDAS® TB-IGRA in the mixed exposure risk population. The dashed line, at 0.35 IU/mL, represents the cut-off that is used for result interpretation. For the VIDAS® TB-

181 IGRA, the cut-off applies to antigen (AG)-negative control (NIL) value. For the QFT-Plus, the
 182 cut-off applies to TB1-NIL and TB2-NIL values. See supplementary table S4 for more details
 183 about the VIDAS® TB-IGRA interpretation algorithm. Values from concordant results were
 184 spread across the measuring interval for both tests, as follows: i) from 0 to 0.35 IU/mL for
 185 concordant negative results (blue boxes on left side of the graph) and ii) from 0.35 IU/mL to the
 186 end of the respective measuring interval of each assay, for concordant positive results (blue
 187 boxes on right side of the graph). For discrepant results with QFT®-Plus positive (red boxes in
 188 green bands), TB1-NIL and TB2-NIL values were grouped more tightly near the cut-off relative
 189 to the positive concordant results. In contrast, when the VIDAS® TB-IGRA was positive (red
 190 box in yellow band), AG-NIL values covered a large portion of the measuring interval, with
 191 several points in the higher half. This suggests that at least a portion of discrepant results were
 192 associated with IFN- γ concentrations far from the cut-off, especially when the VIDAS® TB-
 193 IGRA was positive.

194



195


196

197

198

Supplementary Figure S3. Univariate and multivariate odds ratios determined by logistic regression for aggregate TB exposure risk groups.

199



200 **Supplementary Figure S4.** Univariate and multivariate odds ratios determined by logistic
 201 regression for the three subgroups in the aggregate-high TB exposure risk group.
 202
 203
 204
 205
 206